EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 659 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR An integral part of research September 21, 2022 Trial Suggests Expanded Role for Blinatumomab in Treating ALL January 25, 2023 The ‘major conditions strategy’: will ministers fail to give cancer the... February 6, 2023 Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer February 8, 2022 Load more HOT NEWS Opinion: ‘Medical research charities are falling through the cracks of COVID-19... BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... Studies Delve Deep into the Protein Machinery of Cancer Cells Radiotherapy Can Be Safely Omitted in Older Women with Low-Risk, HR-positive...
